XR Securities’s Gilead Sciences GILD Stock Holding History

XR Securities’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-46,100	Closed	-$53K	–	330
2018 Q4	$53K	Buy	+46,100	New	+$3.22M	0.02%	206

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XR Securities's GILD Position: Q2 2021 in Review

XR Securities sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 5,451 shares — an estimated $352K sold.

XR Securities first reported a position in GILD in Q2 2018 and held it in 8 quarters. The position peaked at $2.42M in Q4 2018. 1,545 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

XR Securities reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
XR Securities sold 5,451 Gilead Sciences shares in Q2 2021, an estimated $352K.
XR Securities first reported a position in Gilead Sciences in Q2 2018 and held it in 8 quarters.
XR Securities's Gilead Sciences position peaked at $2.42M in Q4 2018.
1,545 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on XR Securities's 13F filing for Q2 2021, filed 26 Jul 2021.